Verzenio (abemaciclib) — Medica
Early breast cancer, HR+, HER2-negative, node-positive, high risk of recurrence
Initial criteria
- age ≥ 18 years
- HR+ and HER2-negative breast cancer
- node-positive disease at high risk of recurrence (≥ 4 positive lymph nodes, or 1–3 positive lymph nodes with grade 3 disease or tumor size ≥5 cm)
- Verzenio used in combination with endocrine therapy (tamoxifen or anastrozole, exemestane, or letrozole)
- If pre/perimenopausal woman: receiving ovarian suppression/ablation with GnRH agonist, or had bilateral oophorectomy or ovarian irradiation
- If man: receiving a GnRH analog
Approval duration
2 years